Severity of Respiratory Viral Diseases and the Impacts of Underlying Medical Conditions During the Omicron Subvariant Dominant Epidemics-A Comparative Study of SARS-CoV-2, Influenza Virus and Respiratory Syncytial Virus.

Publication date: May 29, 2025

After the transition of coronavirus disease 2019 (COVID-19) from a pandemic to an endemic phase, data on respiratory viral infections remain limited. This study compared the clinical outcomes of SARS-CoV-2, influenza virus (INFV), and respiratory syncytial virus (RSV) infections and investigated how underlying medical conditions influence disease severity. During Omicron subvariant dominant periods, we conducted a multicenter, retrospective cohort study including laboratory-confirmed cases of SARS-CoV-2, INFV, and RSV infections in hospitalized patients aged ≥ 19 years. We compared demographic characteristics and clinical outcomes and analyzed the association between underlying comorbidities and severity of infection. A total of 1850 cases with SARS-CoV-2, 98 with INFV, and 63 with RSV infections were analyzed. Notable differences in the occurrence of fever, cough, sputum, and dyspnea were observed among patients with the three different viral infections. Pneumonia was diagnosed more frequently in patients with RSV infection (65. 6%) compared to those with INFV infection (42. 9%) and SARS-CoV-2 (34. 4%) (p < 0. 01). For patients with SARS-CoV-2 infection, the risk of pneumonia increased by 47% in the moderate-risk group and 37% in the high-risk group. Among hospitalized patients, pneumonia was more frequently identified in patients with RSV infection, with statistical significance. Furthermore, the presence of medical conditions significantly increased the risk of developing pneumonia.

Open Access PDF

Concepts Keywords
Coronavirus Adult
Covid Aged
Laboratory Comorbidity
Limited comorbidity
Pandemic COVID-19
Epidemics
Female
Hospitalization
Humans
influenza
Influenza, Human
Male
Middle Aged
pneumonia
respiratory syncytial virus
Retrospective Studies
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease MESH Viral Diseases
disease MESH Influenza
disease MESH coronavirus disease 2019
disease MESH infections
disease MESH RSV infections
disease IDO infection
disease MESH dyspnea
disease MESH Pneumonia
pathway REACTOME SARS-CoV-2 Infection
disease MESH Infectious Diseases
disease MESH comorbidity
disease MESH emergency
disease MESH morbidity
disease MESH death
disease MESH alcoholism
pathway KEGG Alcoholism
disease MESH complications
disease MESH acute respiratory distress syndrome
disease MESH chronic conditions
disease IDO history
disease MESH diabetes mellitus
disease MESH cardiovascular disease
disease MESH cerebrovascular disease
disease MESH chronic obstructive pulmonary disease
disease MESH asthma
pathway KEGG Asthma
disease MESH lung diseases
disease MESH chronic renal disease
disease MESH liver disease
disease MESH hematologic malignancy
disease IDO immunodeficiency
drug DRUGBANK Prednisone
disease IDO cell
drug DRUGBANK Trestolone
disease MESH Hypertension
disease MESH Neuromuscular diseases
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH malignancy

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *